Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants

被引:225
|
作者
Maisonneuve, Charles [1 ]
Bertholet, Sylvie [2 ]
Philpott, Dana J. [1 ]
De Gregorio, Ennio [2 ]
机构
[1] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada
[2] Novartis Vaccines & Diagnost, I-53100 Siena, Italy
关键词
NOD1; NOD2; NLRP3; TLR4; alum; BACTERIAL MURAMYL DIPEPTIDE; ACTIVATED PROTEIN-KINASE; DENDRITIC CELLS; NLRP3; INFLAMMASOME; ALUMINUM-HYDROXIDE; NALP3; HOST RECOGNITION; CUTTING EDGE; URIC-ACID; PEPTIDOGLYCAN;
D O I
10.1073/pnas.1400478111
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Innate immunity confers an immediate nonspecific mechanism of microbial recognition through germ line-encoded pattern recognition receptors (PRRs). Of these, Toll-like receptors (TLRs) and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) have shaped our current understanding of innate regulation of adaptive immunity. It is now recognized that PRRs are paramount in instructing an appropriate adaptive immune response. Their ligands have been the focus of adjuvant research with the goal of generating modern vaccine combinations tailored to specific pathogens. In this review we will highlight the recent findings in the field of adjuvant research with a particular focus on the potential of TLR and NLR ligands as adjuvants and their influence on adaptive immune responses.
引用
收藏
页码:12294 / 12299
页数:6
相关论文
共 50 条
  • [1] Toll-like receptor agonists as cancer vaccine adjuvants
    Jeon, Donghwan
    Hill, Ethan
    Mcneel, Douglas G.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [2] The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
    Vasilakos, John P.
    Tomai, Mark A.
    EXPERT REVIEW OF VACCINES, 2013, 12 (07) : 809 - 819
  • [3] Toll-Like Receptor Agonists Are They Good Adjuvants?
    Gnjatic, Sacha
    Sawhney, Nikhil B.
    Bhardwaj, Nina
    CANCER JOURNAL, 2010, 16 (04): : 382 - 391
  • [4] Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents
    Baldridge, JR
    McGowan, P
    Evans, JT
    Cluff, C
    Mossman, S
    Johnson, D
    Persing, D
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) : 1129 - 1138
  • [5] Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
    Kirtland, Max E.
    Tsitoura, Daphne C.
    Durham, Stephen R.
    Shamji, Mohamed H.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [6] Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines
    Stevceva, L.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (33) : 5079 - 5082
  • [7] Toll-like Receptor 9 Agonists as Adjuvants for Nanoparticle-Based Nicotine Vaccine
    Hu, Yun
    Smith, Daniel
    Frazier, Evan
    Zhao, Zongmin
    Zhang, Chenming
    MOLECULAR PHARMACEUTICS, 2021, 18 (03) : 1293 - 1304
  • [8] An in vitro assay to screen Toll-like Receptor agonists as potential adjuvants in allergen immunotherapy
    Kirtland, Max
    Tsitoura, Daphne
    Durham, Stephen
    Shamji, Mohamed
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1527 - 1527
  • [9] Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine
    Vreman, Sandra
    McCaffrey, Joanne
    Popma-de Graaf, Ditta J.
    Nauwynck, Hans
    Savelkoul, Huub F. J.
    Moore, Anne
    Rebel, Johanna M. J.
    Stockhofe-Zurwieden, Norbert
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2019, 212 : 27 - 37
  • [10] Polymer conjugates of toll-like receptor ligands as vaccine adjuvants
    Lynn, G.
    Laga, R.
    Fisher, K.
    Seder, R.
    Seymour, L.
    HUMAN GENE THERAPY, 2011, 22 (10) : A70 - A70